Tillman Gerngross (Adagio)
August 2, 2021 08:58 AM EDTUpdated 10:24 AM
Bioregnum

A glob­al pan­dem­ic fi­as­co sets the stage for Till­man Gern­gross to in­tro­duce his biotech uni­corn to Wall Street

This morn­ing we got a bet­ter look at the num­bers Till­man Gern­gross has in mind for his pan­dem­ic play at Ada­gio Ther­a­peu­tics. And not sur­pris­ing­ly …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

A service from the Financial Times